Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical imiquimod for lentigo maligna
2009-016909-42Phase 4Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Jun 2010
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imiquimod in lentigo maligna (LM), sponsored by University Hospitals Birmingham. Primary endpoint: Pathological complete regression. Started Jun 2010; status: completed.
02
Drugs
imiquimod
03
Conditions
lentigo maligna (LM)
Beyond the preview
Go deeper on 2009-016909-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016909-42.